<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bronchoprovocation testing</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bronchoprovocation testing</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bronchoprovocation testing</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles G Irvin, PhD, FERS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Meredith C McCormack, MD, MHS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Asthma has defied a precise definition acceptable to all, even though clinicians recognize that asthma will present with a constellation of signs and symptoms of intermittent dyspnea, cough, chest tightness, and wheezing. Part of the problem relates to the lack of specificity of these "classic" symptoms of asthma. Despite this uncertainty, the following typical pathophysiologic features both characterize and assist in the diagnostic evaluation of the patient with asthma:</p><p class="bulletIndent1"><span class="glyph">●</span>Reversibility of airflow limitation. This is not always clinically demonstrable, as patients with mild disease often do not have airflow limitation at the time they are tested.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Variable airflow limitation. As an example, patients with allergic asthma may have airflow limitation only after exposure to an asthma trigger or patients with nocturnal asthma only at night. (See  <a class="medical medical_review" href="/d/html/530.html" rel="external">"Allergen avoidance in the treatment of asthma and allergic rhinitis"</a> and  <a class="medical medical_review" href="/d/html/524.html" rel="external">"Nocturnal asthma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperresponsiveness to external triggers. "Twitchy airways" or airway hyperresponsiveness is defined as an excessive response to an aerosolized provocation that elicits little or no response in a normal person. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inflammation of the airways is associated with and may underlie airway hyperresponsiveness [<a href="#rid1">1</a>]. </p><p></p><p>Several types of bronchoprovocation testing are available to assess airway responsiveness in specific patient situations, including pharmacologic challenge, exercise challenge, eucapnic voluntary hyperpnea, food additive challenge, and antigen challenge [<a href="#rid2">2</a>].</p><p>The appropriate use of bronchoprovocation testing in patients with asthma or suspected of having asthma will be reviewed here. The pathogenesis and diagnosis of asthma and the role of bronchoprovocation testing in the diagnosis of occupational asthma are discussed separately. (See  <a class="medical medical_review" href="/d/html/522.html" rel="external">"Pathogenesis of asthma"</a> and  <a class="medical medical_review" href="/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/569.html" rel="external">"Pulmonary function testing in asthma"</a> and  <a class="medical medical_review" href="/d/html/550.html" rel="external">"Occupational asthma: Clinical features, evaluation, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">RATIONALE</span><span class="headingEndMark"> — </span>Measurement of airway responsiveness by bronchoprovocation testing is potentially useful for several reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>Failure to show airway hyperresponsiveness argues against the diagnosis of asthma [<a href="#rid2">2,3</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At any given point in time, airway hyperresponsiveness may be the sole objective evidence of airway dysfunction/asthma [<a href="#rid4">4</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Airway hyperresponsiveness is quantitatively associated with the presence and severity of disease [<a href="#rid5">5-7</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suppression of airway responsiveness is one of the outcomes that can be used to assess new asthma therapies</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The occurrence of airway hyperresponsiveness in an asymptomatic person may help predict the future development of asthma [<a href="#rid4">4</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The degree of airway hyperresponsiveness in a symptomatic person can have prognostic and potentially therapeutic implications [<a href="#rid8">8,9</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The periodicity of asthma exists in parallel with changes in the degree of airway hyperresponsiveness</p><p></p><p>The first four reasons are the ones that are most important clinically; the other reasons are more applicable to research into asthma pathophysiology and the efficacy of asthma medications.</p><p class="headingAnchor" id="H3"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>Indications for bronchoprovocation testing include the accurate diagnosis of asthma in selected patients, assessment of the response to asthma therapy, and, less commonly, identification of triggers for cases involving environmental or occupational exposures [<a href="#rid2">2,10</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Diagnosis of asthma</span><span class="headingEndMark"> — </span>The diagnosis of asthma is often strongly suspected based upon the presence and pattern of typical symptoms that respond to specific therapy for asthma. Many professional groups have long encouraged confirmation of the diagnosis with objective testing that shows reversibility of airflow limitation (eg, before and after bronchodilator, in response to ongoing therapy, or bronchoprovocation challenge) [<a href="#rid11">11,12</a>]. For patients with typical intermittent asthma symptoms and normal baseline spirometry, a clear clinical response to empiric therapy may be adequate diagnostically. However, the cost and side effects of asthma treatment often warrant objective confirmation of the diagnosis with bronchoprovocation testing. Such testing is indicated in several clinical situations where the clinical question is "does this patient really have asthma?", including:</p><p class="bulletIndent1"><span class="glyph">●</span>The patient who has symptoms consistent with asthma but normal pulmonary function test results and no response to a bronchodilator. This situation is commonly encountered in patients with mild or well-managed asthma [<a href="#rid13">13</a>]. Bronchoprovocation testing is the only way to make a positive and objective diagnosis of asthma in this setting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who experience atypical symptoms of bronchospasm and therefore present with complaints not usually associated with asthma (eg, nocturnal awakening).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who present with symptoms that could result from asthma, but are ill-defined or nonspecific (eg, cough) [<a href="#rid14">14,15</a>]. Asthma is one of the important causes of unexplained chronic cough; however, in the absence of bronchial hyperresponsiveness, a diagnosis other than asthma should be considered. (See  <a class="medical medical_review" href="/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are suspected of having occupational asthma, reactive airways dysfunction syndrome, or irritant-induced asthma. (See  <a class="medical medical_review" href="/d/html/536.html" rel="external">"Irritant-induced asthma", section on 'Nonspecific bronchoprovocation challenge'</a> and  <a class="medical medical_review" href="/d/html/550.html" rel="external">"Occupational asthma: Clinical features, evaluation, and diagnosis", section on 'Advanced testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For individuals who require screening test for asthma, such as scuba divers, military personnel, or other individuals in whom bronchospasm would pose an unacceptable hazard.</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Assessment of response to therapy</span><span class="headingEndMark"> — </span>Nonspecific bronchoprovocation challenge is sometimes used in clinical trials as a way to assess the response to a new therapy for asthma [<a href="#rid16">16</a>]. This is particularly useful when evaluating patients with mild asthma not on controller medications whose only physiologic abnormality may be airway hyperresponsiveness and provides an additional and objective endpoint other than symptoms alone. In rare cases, serial bronchoprovocation testing is used to assess the response to avoidance of occupational exposures in occupational asthma, although this is predominantly for research purposes [<a href="#rid17">17</a>]. </p><p class="headingAnchor" id="H6"><span class="h2">Identification of specific asthma triggers</span><span class="headingEndMark"> — </span>Most bronchoprovocation tests use a nonspecific agent (eg, <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a>, <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a>) to assist in making the diagnosis of asthma. On rare occasions, it is necessary to test bronchoreactivity to specific food additives, occupational agents, or environmental antigens. (See  <a class="medical medical_review" href="/d/html/2405.html" rel="external">"Allergic and asthmatic reactions to food additives", section on 'Asthmatic symptoms'</a> and  <a class="medical medical_review" href="/d/html/550.html" rel="external">"Occupational asthma: Clinical features, evaluation, and diagnosis", section on 'Specific inhalation challenge'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">PRECAUTIONS</span><span class="headingEndMark"> — </span>Bronchial challenge with nonspecific agents (eg, <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a>, <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a>) is safe and easy to perform, as long as appropriate precautions are taken [<a href="#rid2">2,13,18,19</a>]. Guidelines regarding patient preparation and contraindications to methacholine challenge are listed in the tables  (<a class="graphic graphic_table graphicRef82058" href="/d/graphic/82058.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef62151" href="/d/graphic/62151.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef51312" href="/d/graphic/51312.html" rel="external">table 3</a>) [<a href="#rid2">2,3</a>]. Personnel performing the test should be able to recognize severe bronchospasm; a rapid acting beta agonist (eg, <a class="drug drug_general" data-topicid="9396" href="/d/drug information/9396.html" rel="external">albuterol</a>) should be immediately available either as a metered dose inhaler or nebulizer treatment [<a href="#rid2">2,3,20</a>]. Demonstration that the FEV<sub>1</sub> has returned to or exceeded baseline should be obtained before the patient leaves the pulmonary function laboratory. Resuscitation equipment should also be available. </p><p>Patients with unstable cardiac disease or a myocardial infarction or stroke within the past three months are excluded from bronchoprovocation testing due to the physical exertion of the repeated measurements of spirometry  (<a class="graphic graphic_table graphicRef82058" href="/d/graphic/82058.html" rel="external">table 1</a>). However, among adults without cardiac disease, the risk of adverse cardiac effects appears minimal [<a href="#rid21">21</a>].</p><p>Bronchoprovocation challenge should only be initiated in the absence of signs or symptoms of significant airflow obstruction. In patients with significant baseline impairment in the forced expiratory volume in one second (FEV<sub>1</sub>), a bronchodilator reversibility study is usually indicated instead of bronchoprovocation  (<a class="graphic graphic_algorithm graphicRef60462" href="/d/graphic/60462.html" rel="external">algorithm 1</a>). Cutoff values below which bronchoprovocation testing is not routinely performed vary; guidelines suggest exclusion of patients with an FEV<sub>1</sub> &lt;60 percent predicted (adults or children), or an FEV<sub>1</sub> &lt;1.5 liters (adults) [<a href="#rid2">2,3,18</a>]. We typically do not perform a bronchoprovocation challenge in a patient with an FEV<sub>1</sub> &lt;70 percent predicted unless a physician is present.</p><p>The safety of bronchoprovocation with <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> for patients with a baseline FEV<sub>1</sub> &lt;60 percent predicted was evaluated in 88 patients who underwent methacholine challenge testing [<a href="#rid22">22</a>]. In this study, all but 4 of 88 patients returned to &gt;90 percent of their baseline FEV<sub>1</sub> following a single inhaled beta-agonist treatment, and the four nonresponders improved satisfactorily after a second treatment. No patients in this study experienced any adverse sequelae. However, bronchoprovocation testing in patients with this degree of baseline airflow obstruction should only be performed with caution.</p><p class="headingAnchor" id="H11359060"><span class="h1">ENSURING ADEQUATE SPIROMETRY</span><span class="headingEndMark"> — </span>Reproducible spirometry is key to the performance of bronchoprovocation testing. Nose clips help to prevent leakage through the nasal passages and improve reliability. The testing requires multiple spirometric maneuvers, so it is important to explain to the patient the need for maximal and vigorous efforts and the importance of deep inhalation to full lung capacity for each maneuver. Depending on the protocol used, the exhalation time is six seconds (most common) or two seconds (sometimes called a forced expiratory volume in one second [FEV<sub>1</sub>] maneuver). The shorter time may be used to decrease the respiratory effort and is often acceptable when vocal cord dysfunction is not a concern. When vocal cord dysfunction is suspected, a full flow volume loop is needed. Usually, two spirometric maneuvers are obtained at baseline and at each time point of the test. Details about proper coaching of patients during testing and assessing the adequacy of the flow-volume or FEV<sub>1</sub> tracing are provided separately. (See  <a class="medical medical_review" href="/d/html/6968.html" rel="external">"Office spirometry", section on 'Coaching the patient'</a> and  <a class="medical medical_review" href="/d/html/6968.html" rel="external">"Office spirometry", section on 'Adequacy of test'</a>.)</p><p>During the testing, the spirometric tracings are observed to make sure that the patient has fully inhaled to total lung capacity (TLC) prior to performing the expiratory maneuver. If the patient does not fully inhale to TLC, a decrease in FEV<sub>1</sub> can occur without bronchoconstriction and cause a false positive result [<a href="#rid23">23</a>]. Generally, forced vital capacity (FVC) is not used as an outcome measure for bronchoprovocation. Decreases in FVC usually reflect an inadequate inspiratory effort, incomplete exhalation, or an increase in residual volume (RV) due to airtrapping. Reports show that obesity and asthma cause an increase in the relative fall in FVC [<a href="#rid24">24</a>].</p><p>For patients who have difficulty performing spirometry that meets acceptability standards, measures of airway resistance such as the forced oscillation technique or specific airway conductance (sGaw) [<a href="#rid25">25</a>], which require little or less patient effort, can be used as alternative end-points [<a href="#rid3">3,16</a>]. Usually changes in sGaw mirror changes in FEV<sub>1</sub>, although sGaw changes are more variable. Thus, a larger percent change in sGaw (eg, 45 percent) is required for a positive test. (See  <a class="medical medical_review" href="/d/html/569.html" rel="external">"Pulmonary function testing in asthma", section on 'Bronchodilator responses'</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">PHARMACOLOGIC CHALLENGE</span><span class="headingEndMark"> — </span>Pharmacologic challenge procedures determine the dose-response characteristics of the airways to a provocative challenge [<a href="#rid26">26</a>]. When performing inhalational challenges, it is crucial that the solutions and nebulizer apparatus are prepared in a standardized fashion [<a href="#rid2">2,3</a>].</p><p>Depending on the indication for testing, some or all of the patients’ medications may need to be stopped prior to testing  (<a class="graphic graphic_table graphicRef62151" href="/d/graphic/62151.html" rel="external">table 2</a>) [<a href="#rid2">2,27</a>]. Generally, inhaled glucocorticoids (ICS) are not stopped as it takes three weeks for the effect to wear off. However, a negative test while the patient is using ICS implies that the patient’s current symptoms are not due to asthma but does not rule out underlying asthma. To exclude airways hyperresponsiveness, the test would need to be repeated at least three weeks after discontinuation of ICS and when the patient has asthma like symptoms. In addition, a cohort-control study of patients taking controller medication for asthma found that the sensitivity of <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> challenge is lower in White patients and non-atopic patients, than in African American and atopic patients [<a href="#rid28">28</a>]. </p><p class="headingAnchor" id="H5623382"><span class="h2">Delivery of pharmacologic agents</span><span class="headingEndMark"> — </span>A number of provocative agents are administered via a nebulizer device (eg, <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a>, histamine, <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a>). The dose of a provocative agent that actually reaches the intrathoracic airways from an aerosol device can be difficult to quantify, but is the basis of the European Respiratory Society Technical Standard for methacholine inhalation challenge [<a href="#rid2">2</a>]. Measurement of nebulizer output (typically by the manufacturer) is used to determine the appropriate dilutions of methacholine for the particular nebulizer. This enables delivery of the desired methacholine dose during the nebulization time. The relative importance of other factors (eg, aerosol particle size, respiratory pattern) that may influence aerosol delivery is less well-characterized [<a href="#rid29">29-32</a>].</p><p>In order to improve test standardization, it is advised that the aerosol amount be reported as the dose of the agonist (microg) rather than the concentration (mg/mL). Increasing doses or concentrations of the provoking agent (eg, <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a>, histamine) are followed by spirometry at each step to generate a reproducible dose-response curve. In an attempt to standardize the delivered dosage, the agent is inhaled via a standardized aerosol delivery system (eg, an output of 0.13 mL/min) while the subject performs a specific breathing maneuver [<a href="#rid2">2,29,33</a>].  </p><p>The preferred breathing maneuver uses a defined period (eg, at least one minute) of quiet (tidal volume) breathing [<a href="#rid2">2,18,34-36</a>]. The method of five vital capacity breaths followed by a breathhold is not equivalent to the quiet breathing method for patients with mild hyperresponsiveness, probably due to the protective and bronchodilator effects of large vital capacity breaths [<a href="#rid34">34</a>]. Therefore, the quiet or tidal volume breathing method yields greater sensitivity. Alternatively, the five inhalations followed by breathhold can be modified to use a submaximal inhalation, approximately 50 or 60 percent below total lung capacity, followed by a breathhold [<a href="#rid23">23,34,37</a>].  </p><p class="headingAnchor" id="H10"><span class="h2">Choice of agents</span><span class="headingEndMark"> — </span>Bronchial challenge tests are often classified as direct or indirect based on postulated mechanisms. Direct stimuli, such as <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> and histamine, are thought to cause bronchoconstriction via direct stimulation of airway smooth muscle receptors, whereas indirect stimuli (eg, <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a>, <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a> monophosphate, eucapnic hyperventilation) cause bronchoconstriction through one or more intermediate pathways, typically involving release of inflammatory mediators (eg, prostaglandin D2, leukotriene E4) from mast cells [<a href="#rid38">38</a>]. However, direct stimuli such as histamine or methacholine also affect other cells besides smooth muscle, such as nerves and mucous containing cells, so this distinction is somewhat artificial.</p><p>Histamine has been used in research studies of bronchial challenge, but is much less commonly employed clinically than <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a>, due to its frequent induction of flushing and headaches [<a href="#rid39">39</a>]. In addition, histamine is not commercially available for this clinical use. Methacholine and histamine challenge appear to give equivalent results in selected groups of asthmatic subjects, but in theory, they are not equivalent challenges since they stimulate different receptors and histamine is known to activate airway neural reflexes [<a href="#rid35">35,40</a>].</p><p>Other compounds that have been used or advocated for use in bronchoprovocation challenge include bradykinin, <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a> monophosphate (AMP), hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, and <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> [<a href="#rid33">33,41-54</a>]. As an example, one study comparing serial AMP and <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> challenge testing in 120 asthmatics found that AMP was more closely associated with other markers of airway inflammation, and more sensitive to subtle changes in airway responsiveness [<a href="#rid44">44</a>]. Administration of these compounds appears to distinguish patients with asthma from normal subjects; however, clinical experience is more limited than with methacholine or histamine. In addition, normative data on the expected effect of inhaled AMP in normal control subjects is lacking [<a href="#rid55">55</a>]. </p><p>In general, it appears that <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> is more sensitive for airway hyperresponsiveness, but less specific than <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a>, and mannitol results are more in agreement with exercise challenge [<a href="#rid33">33,56,57</a>]. The optimal roles of methacholine and mannitol challenge in the assessment of airway hyperresponsiveness for clinical purposes remain unclear. Since the challenge modalities are not equivalent, this supports the notion that airway hyperresponsiveness is the expression of more than one mechanism as seen with animal models.</p><p class="headingAnchor" id="H11"><span class="h3">Methacholine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">Methacholine</a>, a derivative of acetylcholine, is the agent most commonly used for bronchoprovocation and is an acceptable form of bronchoprovocation for assessing asthma in Olympic athletes [<a href="#rid58">58</a>]. Bronchoconstriction due to methacholine is of longer duration than that due to acetylcholine, thus facilitating measurement of the response. The American Thoracic Society and the European Respiratory Society have published guidelines regarding methacholine challenge testing procedures  (<a class="graphic graphic_table graphicRef82058" href="/d/graphic/82058.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef62151" href="/d/graphic/62151.html" rel="external">table 2</a> and <a class="graphic graphic_algorithm graphicRef60462" href="/d/graphic/60462.html" rel="external">algorithm 1</a>) [<a href="#rid2">2,3,10,18</a>].</p><p>A series of <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> chloride solutions are prepared, ranging from approximately 0.016 to 0.03 mg/mL (the most dilute) to 16 mg/mL (the most concentrated). As shown in the table, these solutions are usually prepared in two-fold or four-fold dilutions  (<a class="graphic graphic_table graphicRef51312" href="/d/graphic/51312.html" rel="external">table 3</a>) [<a href="#rid2">2</a>].</p><p>After baseline spirometry that meets criteria noted elsewhere (see  <a class="medical medical_review" href="/d/html/6968.html" rel="external">"Office spirometry", section on 'Adequacy of test'</a>), usually the diluent is administered by nebulizer during tidal breathing for at least one minute (see <a class="local">'Delivery of pharmacologic agents'</a> above), although it is also acceptable to start with the most dilute concentration of <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a>. After inhalation of the aerosol, the forced expiratory volume in one second (FEV<sub>1</sub>) is measured at 30 and 90 seconds with careful coaching of the subject to obtain an acceptable quality FEV<sub>1</sub>. Each time two maneuvers are performed; if FEV<sub>1</sub> is the only outcome being measured, it is acceptable to shorten the expiratory time to about two seconds (from the usual six seconds), unless there is a suspicion of vocal cord dysfunction in which case a full vital capacity maneuver with inspiratory and expiratory phases is performed. </p><p>The dose or concentration of <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> is sequentially increased one step at a time  (<a class="graphic graphic_table graphicRef51312" href="/d/graphic/51312.html" rel="external">table 3</a>), until a decrease in FEV<sub>1</sub> greater than 20 percent or a 35 to 40 percent decrease in specific airways conductance (sGaw) is observed [<a href="#rid2">2,3,18,30</a>]. Typically, when there is a positive test, the FEV<sub>1</sub> decreases more than 20 percent, so the dose of the inhaled agent that would provoke a 20 percent drop in FEV<sub>1</sub> is determined by interpolation. This is referred to as the provocative dose or PD20. Generally, a methacholine PD20 of 200 microg or a PC20 of 8 mg/mL (100 microg or 4 mg/mL, for sGaw) or less is considered a positive test [<a href="#rid2">2</a>]. A PD20 greater than 400 microg (PC20 greater than 16 mg/mL) is considered a negative test [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H22416491"><span class="h3">Mannitol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">Mannitol</a> inhalation is thought to cause bronchoconstriction by increasing the osmolarity of the airway surface, resulting in release of mast cell mediators. The mast cell mediators (eg, prostaglandin D2, leukotriene E4) in turn cause bronchoconstriction. The guidelines published by the American Thoracic Society and the European Respiratory Society for <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> challenge testing procedures are also appropriate for mannitol bronchoprovocation  (<a class="graphic graphic_table graphicRef82058" href="/d/graphic/82058.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef62151" href="/d/graphic/62151.html" rel="external">table 2</a>) [<a href="#rid3">3,18</a>]. </p><p><a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">Mannitol</a> for bronchoprovocation is prepared as a dry powder in capsules containing graduated doses that are administered via a dry powder inhaler (Aridol) [<a href="#rid52">52,59</a>]. It is available in a number of countries, including Australia, Canada, Germany, Korea, United Kingdom, and United States. Due to the use of premeasured doses, mannitol inhalation challenge may prove to be more convenient than challenges with <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a>, exercise, or isocapnic hyperventilation.</p><p>For the bronchoprovocation procedure, <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> dry powder is rapidly inhaled in progressively increasing doses (0, 5, 10, 20, 40, 80, 160, 160, 160 mg). The FEV<sub>1</sub> is measured at baseline and repeated at one minute after each dose; the highest of two repeatable values is used [<a href="#rid34">34,51</a>]. If the FEV<sub>1</sub> decreases by 10 percent after a dose then that dose is repeated. A 15 percent fall in FEV<sub>1</sub> at a total cumulative dose of ≤635 mg (known as the provocative dose or PD 15) is considered a positive response, as is a persistent decrease of 10 percent between consecutive doses. </p><p><a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">Mannitol</a> challenge appears to be safe; among 592 subjects with and without asthma who underwent mannitol bronchoprovocation, no serious adverse events were noted [<a href="#rid50">50</a>]. However, cough is a common side effect [<a href="#rid49">49,50</a>].</p><p class="headingAnchor" id="H5623764"><span class="h2">Interpretation</span><span class="headingEndMark"> — </span>To interpret a bronchoprovocation challenge test, a graph is drawn plotting the fall in the outcome indicator (eg, forced expiratory volume in one second [FEV<sub>1</sub>]) versus the dose or concentration of the provocative agent  (<a class="graphic graphic_figure graphicRef82365" href="/d/graphic/82365.html" rel="external">figure 1</a>). The effective dose or concentration that would have resulted in a given change in the outcome indicator is determined by interpolation. This dose of the provocative agent (eg, provocative dose or concentration of <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> for a 20 percent fall in the FEV<sub>1</sub> or provocative dose of <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> for a 15 percent fall in FEV<sub>1</sub>) is used to interpret the test. </p><p>Through experience with each agent, doses and concentrations in the normal, asthmatic, and indeterminate (for <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a>) ranges have been ascertained. </p><p class="bulletIndent1"><span class="glyph">●</span>As noted above, the PD20-FEV<sub>1 </sub>for <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> in patients with asthma is usually 200 microg (PC20 8 mg/mL), or less. A graded system of borderline (100 to 400 microg, 4 to 16 mg/mL), mild (25 to 100 microg, 1 to 4 mg/mL), moderate (6 to 25 microg, 0.25 to 1 mg/mL), and marked (&lt;6 microg, &lt;0.25 mg/mL) airway hyperresponsiveness has been proposed, although the clinical utility has not been fully determined [<a href="#rid2">2</a>]. (See <a class="local">'Methacholine'</a> above.)</p><p></p><p class="bulletIndent1">It is difficult to calculate the exact sensitivity of a <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> challenge for the diagnosis of asthma, as a gold standard for diagnosing asthma does not exist. On the other hand, for a cut-point of 200 to 400 microg (8 to 16 mg/mL) using a non-deep inhalation method, the sensitivity is felt to approach 100 percent [<a href="#rid33">33,60,61</a>]. The positive predictive value is more limited (estimated around 50 percent for a cut-point of 200 microg [8mg/mL]), as false positive results may be seen in patients with allergic rhinitis, cystic fibrosis, heart failure, chronic obstructive pulmonary disease (COPD), and bronchitis [<a href="#rid2">2,3,33</a>]. Thus, the negative predictive value is the most useful aspect of methacholine challenge. (See <a class="local">'Asymptomatic patient, positive test'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For incremental <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> bronchoprovocation testing, the test is negative when the final FEV<sub>1</sub> has not decreased by ≥15 percent from baseline or by ≥10 percent from the previous dose [<a href="#rid59">59</a>]. (See <a class="local">'Mannitol'</a> above.)</p><p></p><p class="headingAnchor" id="H5623771"><span class="h2">Difficult interpretations</span><span class="headingEndMark"> — </span>The results of bronchoprovocation testing can be difficult to interpret when a patient with a positive test has no symptoms of asthma, or when a patient with a negative result has symptoms suggestive of asthma.</p><p class="headingAnchor" id="H5623778"><span class="h3">Asymptomatic patient, positive test</span><span class="headingEndMark"> — </span>Epidemiologic studies indicate that approximately 1 to 7 percent of the population have reactive airways (up to 26 percent if smokers are included) but are otherwise normal or asymptomatic [<a href="#rid62">62-64</a>]. These individuals may represent the "tail" of a normal bell-shaped population [<a href="#rid62">62</a>], or alternatively they may have asthma but do not perceive any symptoms [<a href="#rid3">3,14</a>]. The latter possibility is supported by the observations that poor perception of airflow limitation occurs in some asthmatics who are at risk for unexpected exacerbations [<a href="#rid14">14</a>], and subjects with "laboratory asthma" may in fact subsequently develop a clinical diagnosis of asthma [<a href="#rid4">4,65</a>].</p><p class="headingAnchor" id="H5623785"><span class="h3">History suggestive of asthma, negative test</span><span class="headingEndMark"> — </span>Many studies report that airway hyperresponsiveness, as measured by a <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> PC20, is consistent and reproducible in asthmatics; however, these studies largely evaluated patients with stable asthma. The following clinical settings are examples of situations in which a patient may report a convincing history of asthma but have a negative challenge.</p><p class="bulletIndent1"><span class="glyph">●</span>The inhalation of an antigen with a subsequent late asthmatic response, as seen in certain occupational exposures. After resolution of the late asthmatic response, many patients are hyperresponsive for weeks, but gradually return to normal [<a href="#rid1">1</a>]. On the other hand, some patients show a rapid resolution of hyperresponsiveness. As a result, it is very important to relate the PC20 result to the presence or absence of current respiratory symptoms and exposures. Asthma is, by definition, a variable disease state and likewise hyperresponsiveness can wax and wane and not be reproducible [<a href="#rid66">66,67</a>]. (See  <a class="medical medical_review" href="/d/html/550.html" rel="external">"Occupational asthma: Clinical features, evaluation, and diagnosis", section on 'Advanced testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Paradoxical vocal cord motion (also known as vocal cord dysfunction) may result in symptoms suggestive of asthma but a negative challenge test result, if the only endpoint is the change in FEV<sub>1</sub>. This condition is often detected by careful inspection of the inspiratory flow-volume relationship. Patients may have predominantly inspiratory or expiratory vocal cord dysfunction, with corresponding inspiratory or expiratory abnormalities on the flow-volume loop  (<a class="graphic graphic_figure graphicRef76811" href="/d/graphic/76811.html" rel="external">figure 2</a>). (See <a class="local">'History suggestive of asthma, atypical spirometry pattern'</a> below and  <a class="medical medical_review" href="/d/html/523.html" rel="external">"Inducible laryngeal obstruction (paradoxical vocal fold motion)"</a> and  <a class="medical medical_review" href="/d/html/1465.html" rel="external">"Flow-volume loops"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central airway obstruction by a tumor, polyp, or foreign body can also mimic asthma symptomatically, but results in a negative <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> challenge. (See  <a class="medical medical_review" href="/d/html/4387.html" rel="external">"Airway foreign bodies in adults"</a> and  <a class="medical medical_review" href="/d/html/4384.html" rel="external">"Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults", section on 'Diagnostic evaluation and initial management'</a>.)</p><p></p><p class="headingAnchor" id="H7554031"><span class="h3">History suggestive of asthma, atypical spirometry pattern</span><span class="headingEndMark"> — </span>Upper airway responses to various challenge procedures are common and can lead to confusing results [<a href="#rid68">68</a>]. As an example, patients with vocal cord dysfunction may develop flattening of the inspiratory portion of the flow volume loop in response to pharmacologic bronchoprovocation challenge. Fortunately, this can usually be detected if full inspiratory as well as expiratory flow-volume loops are performed and inspected, although direct laryngoscopy may be required to confirm the diagnosis [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/523.html" rel="external">"Inducible laryngeal obstruction (paradoxical vocal fold motion)"</a> and  <a class="medical medical_review" href="/d/html/1465.html" rel="external">"Flow-volume loops"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">EXERCISE CHALLENGE</span><span class="headingEndMark"> — </span>Exercise is thought to be a trigger for bronchoconstriction in virtually all patients with hyperreactive airways and may be the only trigger for a subset of patients with asthma [<a href="#rid40">40</a>]. The identification of exercise-induced bronchoconstriction (EIB) and the documentation of its successful treatment are important and practical considerations for children and active adults [<a href="#rid69">69</a>]. Guidelines from the American Thoracic Society (ATS) state that symptoms alone are inadequate to diagnose EIB, and a challenge test with serial lung function measurements is necessary [<a href="#rid70">70</a>]. Graded exercise in a monitored setting provides an objective test for the evaluation and management of EIB; eucapnic voluntary hyperventilation (EVH) is an alternative. (See  <a class="medical medical_review" href="/d/html/533.html" rel="external">"Exercise-induced bronchoconstriction"</a>.) </p><p>Bronchodilator therapy is withheld prior to testing  (<a class="graphic graphic_table graphicRef62151" href="/d/graphic/62151.html" rel="external">table 2</a>), as bronchodilators can block a bronchospastic response to exercise testing, causing a false negative result. After vigorous exercise, some patients have a refractory period during which EIB is suppressed, so vigorous exercise should also be avoided the day of the testing.</p><p>The presence of EIB is determined using the following general protocol [<a href="#rid3">3,71</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Baseline spirometry values are determined by obtaining two reproducible maneuvers within 3 percent of each other; the best maneuver is used to calculate post exercise falls in FEV<sub>1</sub> [<a href="#rid71">71</a>]. If vocal cord dysfunction is suspected, full inspiratory and expiratory maneuvers are performed before and after exercise.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring during the test generally includes a continuous electrocardiogram, blood pressure, pulse oximetry, and minute ventilation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Airway drying caused by the increased minute ventilation during exercise is thought to be the stimulus for exercise-induced bronchoconstriction, so careful control of the temperature and humidity of the inhaled air are needed to ensure test reliability [<a href="#rid70">70,72,73</a>]. The ATS guidelines suggest having the patient breathe dry air (&lt;10 mg H<sub>2</sub>O/L air), which can be administered via a gas cylinder with a reservoir bag (Douglas bag apparatus) and a one-way mouth valve [<a href="#rid70">70,71</a>]. Nose clips should be worn during the test to avoid entrainment of ambient air.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The preferred modes of exercise are either a motor-driven treadmill or the electromagnetically braked cycle ergometer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The exercise protocol is selected to allow the patient to achieve 80 to 90 percent of predicted maximum heart rate (estimate at 220 minus age in years) in the first two minutes of exercise and maintain it for the remaining eight minutes of the test. Patients should reach 40 to 60 percent of their predicted maximum voluntary ventilation (MVV). The predicted MVV can be calculated by taking the pretest FEV<sub>1</sub> and multiplying by a factor between 35 and 40; for convenience 40 is widely used [<a href="#rid74">74</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spirometry is performed prior to exercise, and at 5, 10, 15, 20, and 30 minutes thereafter [<a href="#rid3">3</a>]. It is important to assess lung function serially after exercise, as bronchoconstriction usually occurs 10 to 15 minutes after the end of exercise.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A test is considered positive if the forced expiratory volume in one second (FEV<sub>1</sub>) decreases by 10 percent, although a fall of 15 percent is more diagnostic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A high prevalence of positive tests is observed in elite athletes [<a href="#rid75">75</a>], and the prevalence in recreationally active subjects approaches 13 percent [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asthma symptoms and bronchoconstriction provoked by the testing are treated with inhalation of a short-acting beta agonist (eg, <a class="drug drug_general" data-topicid="9396" href="/d/drug information/9396.html" rel="external">albuterol</a>). (See <a class="local">'Precautions'</a> above.)</p><p></p><p>An inadequate exercise stimulus that fails to raise the minute ventilation sufficiently is the most common problem with this test and may result in a false negative result. If this occurs, other provocative maneuvers that may elicit bronchospasm include free running, the addition of cold air, or eucapnic voluntary hyperpnea [<a href="#rid72">72,77,78</a>]. </p><p>For patients with a positive exercise challenge test, the efficacy of preventative medications (eg, short-acting beta agonist, antileukotriene agent) can be assessed by repeating the test on medication, although this is not necessary in most patients [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H5620471"><span class="h1">EUCAPNIC VOLUNTARY HYPERPNEA</span><span class="headingEndMark"> — </span>Eucapnic voluntary hyperpnea (EVH, also known as isocapnic voluntary hyperventilation) is another type of challenge for assessing airway hyperresponsiveness. It is thought that dry air hyperventilation causes drying and hyperosmolarity of the airway surface (similar to the effect of exercise), resulting in release of inflammatory mediators from inflammatory cells such as mast cells (similar to <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> inhalation) [<a href="#rid71">71</a>]. EVH is one of the recommended challenge tests for identifying exercise-induced bronchoconstriction (EIB) in Olympic athletes [<a href="#rid58">58,79,80</a>]; EIB is the leading medical problem in elite athletes [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/d/html/533.html" rel="external">"Exercise-induced bronchoconstriction"</a>.)  </p><p>For the procedure, baseline spirometry is performed twice to obtain two values for forced expiratory volume in one second (FEV<sub>1</sub>) that are reproducible; the best value for FEV<sub>1</sub> is used to calculate the post challenge changes. The patient wears nose clips and orally inhales a mixture of dry hypercapnic air (4.5 to 5 percent CO<sub>2</sub>, 21 percent O<sub>2</sub>, balanced N<sub>2</sub>). The hypercapnic air ensures that the subject remains eucapnic during the test, as hypocapnia can cause bronchoconstriction. It is not necessary to chill the inspired air as it is believed that the water content and not the air temperature is the essential feature that leads to bronchoconstriction in patients with airway hyperresponsiveness [<a href="#rid71">71,81</a>].</p><p>The patient is instructed to breathe the dry hypercapnic air for six minutes at a minute ventilation of 30 times the baseline FEV<sub>1</sub> [<a href="#rid70">70,80,82</a>]. For subjects who are unable to achieve this target, the minimum ventilation for a valid test for untrained subjects is 21 times the FEV<sub>1</sub> [<a href="#rid70">70,83</a>]. After the completion of the challenge, two reproducible postexercise spirometry maneuvers are performed at each time point of 5, 10, and 15 minutes. A test is generally considered positive if the FEV<sub>1</sub> decreases by 10 percent or more [<a href="#rid58">58,80</a>].</p><p class="headingAnchor" id="H26846610"><span class="h1">ANTIGEN CHALLENGE</span><span class="headingEndMark"> — </span>The accurate identification of a specific inhaled allergen by antigenic challenge is largely a research tool for investigation of mechanisms of asthma, the efficacy of new therapeutic agents, and suspected occupational allergens [<a href="#rid3">3,84</a>]. Allergen inhalation challenge is a specialized procedure and should not be undertaken by individuals unfamiliar with the technique. Some patients may have a severe response requiring hospitalization. </p><p>Bronchoprovocation tests with specific occupational agents should only be performed in specialized centers, and may require over 24 hours of monitoring following the challenge procedure to detect and, if necessary, treat a late asthmatic response [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/d/html/550.html" rel="external">"Occupational asthma: Clinical features, evaluation, and diagnosis", section on 'Specific inhalation challenge'</a>.)</p><p class="headingAnchor" id="H26846649"><span class="h1">ASPIRIN CHALLENGE</span><span class="headingEndMark"> — </span>Aspirin-exacerbated respiratory disease (AERD) is characterized by asthma, chronic rhinosinusitis with nasal polyposis, and reactions to ingestion of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> or other cyclo-oxygenase-1 inhibiting nonsteroidal anti-inflammatory drugs (NSAIDs). The reactions to aspirin and NSAIDs typically begin 30 minutes after ingestion and involve marked nasal congestion and bronchospasm. Oral aspirin challenge is performed in patients with suspected AERD who have a medical indication for aspirin or NSAID therapy at a time when their asthma is under good control.</p><p>The technique for <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> challenge requires safeguards such as premedication with a leukotriene modifying agent (eg, <a class="drug drug_general" data-topicid="9539" href="/d/drug information/9539.html" rel="external">montelukast</a>), ensuring that the patient’s asthma is well-controlled at the time of challenge, performing the challenge in a medically-monitored setting, and obtaining intravenous access prior to the challenge. A detailed description of the challenge procedure is provided separately. (See  <a class="medical medical_review" href="/d/html/2085.html" rel="external">"Diagnostic challenge and desensitization protocols for NSAID reactions"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">FOOD ADDITIVE CHALLENGE</span><span class="headingEndMark"> — </span>Another form of bronchoprovocation testing involves challenge with food additives, which can be useful in patients who describe food intolerances. Sulfites (found in food preservatives as an antioxidant) and tartrazine (found in orange food color) are the food additives most commonly studied [<a href="#rid86">86-90</a>]. Oral ingestion of sulfites may result in bronchoconstriction due to the inhalation of sulfur dioxide (SO<sub>2</sub>), which is produced by the acidification of metabisulfite in the stomach [<a href="#rid89">89</a>].</p><p>The interpretation of the results of food additive challenge is difficult because one can only estimate the amount of dietary exposure from these preservatives. Nevertheless, since the response to these agents can be quite severe, a negative test result can be clinically important, because it will free patients from concern about the ingestion of these compounds.</p><p>A bronchospastic response to a food additive is a relatively uncommon problem in asthma, since less than 5 percent of the asthmatic population is thought to be sensitive to these compounds [<a href="#rid91">91</a>]. Testing, which should be done in specialized laboratories, involves blinded challenge with the agent in question and serial monitoring of lung function.</p><p>Oral food challenges for the diagnosis of food allergy are discussed separately. (See  <a class="medical medical_review" href="/d/html/2399.html" rel="external">"Oral food challenges for diagnosis and management of food allergies", section on 'Performance of an OFC'</a>.)</p><p class="headingAnchor" id="H2211220863"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/122209.html" rel="external">"Society guideline links: Exercise-induced bronchoconstriction"</a> and  <a class="medical medical_society_guidelines" href="/d/html/118218.html" rel="external">"Society guideline links: Pulmonary function testing"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchoprovocation types</strong> – Several types of bronchoprovocation testing are available to assess airway responsiveness in specific patient situations. These include pharmacologic challenge, exercise challenge, eucapnic voluntary hyperpnea, food additive challenge, and antigen challenge. (See <a class="local">'Rationale'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic bronchoprovocation testing</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications</strong> – Pharmacologic bronchoprovocation testing (eg, <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a>, <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a>) is indicated when the diagnosis of asthma is in question (eg, symptoms are atypical, baseline spirometry is normal); when a patient is suspected of having occupational asthma, reactive airways dysfunction syndrome (RADS), or irritant-induced asthma; and when a screening test for asthma is required for scuba divers, military personnel, or other individuals in whom bronchospasm would pose an unacceptable hazard. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Contraindications and medication requirements</strong> – The contraindications to bronchoprovocation challenge and a list of medications that need to be discontinued prior to testing are listed in the tables  (<a class="graphic graphic_table graphicRef82058" href="/d/graphic/82058.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef62151" href="/d/graphic/62151.html" rel="external">table 2</a>). (See <a class="local">'Pharmacologic challenge'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Methacholine</strong><strong> challenge</strong> – <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">Methacholine</a> inhalation challenge is the most common type of pharmacologic challenge. Patients breathe progressively stronger doses of methacholine according to a protocol  (<a class="graphic graphic_algorithm graphicRef60462" href="/d/graphic/60462.html" rel="external">algorithm 1</a>). The dose of methacholine that provokes a 20 percent drop in forced expiratory volume in one second (FEV<sub>1</sub>) is referred to as the PD20. Generally, a PD20 of 200 to 400 microg (PC20 8 mg/mL) methacholine or less is considered a positive test. (See <a class="local">'Pharmacologic challenge'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mannitol</strong><strong> challenge</strong> – <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">Mannitol</a> inhalation challenge is mediated by release of bronchoconstrictive mediators. Mannitol challenge is performed by oral inhalation of a dry powder at progressively increasing doses. A 15 percent fall in FEV<sub>1</sub> at a total cumulative dose of ≤635 mg (known as the provocative dose or PD15) is considered a positive response. (See <a class="local">'Mannitol'</a> above and <a class="local">'Interpretation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchoprovocation for exercise-induced bronchospasm</strong> – Exercise testing and eucapnic voluntary hyperpnea (EVH) are forms of bronchoprovocation used for patients with symptoms suggestive of asthma during exercise, but with normal spirometry at rest. (See <a class="local">'Exercise challenge'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Exercise challenge</strong> – For formal exercise challenge tests, the patient is exercised on a treadmill or cycle ergometer to 80 to 90 percent of predicted maximum heart rate for six to eight minutes. Patients should reach 40 to 60 percent of their predicted maximum voluntary ventilation. Spirometry is performed prior to exercise, and at 5, 10, 15, 20, and 30 minutes thereafter. A test is generally considered positive if the FEV<sub>1</sub> decreases by 10 percent, although a fall of 15 percent is more diagnostic. (See <a class="local">'Exercise challenge'</a> above and  <a class="medical medical_review" href="/d/html/533.html" rel="external">"Exercise-induced bronchoconstriction"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Eucapnic voluntary hyperpnea</strong> – For eucapnic voluntary hyperpnea testing, the patient breathes dry hypercapnic air for six minutes at a minute ventilation of 30 times the FEV<sub>1</sub>. Spirometry is performed prior to the test, and at 5, 10, and 15 minutes after completion. A test is generally considered positive if the FEV<sub>1</sub> decreases by 10 percent or more. (See <a class="local">'Eucapnic voluntary hyperpnea'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergen challenge</strong> – Inhalation of nebulized allergens (eg, dust mite, animal danders, occupational agents) carries greater risk and is reserved for research purposes, occupational asthma, and rare clinical situations. (See <a class="local">'Antigen challenge'</a> above and  <a class="medical medical_review" href="/d/html/550.html" rel="external">"Occupational asthma: Clinical features, evaluation, and diagnosis", section on 'Specific inhalation challenge'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspirin</strong><strong> challenge</strong> – The indications, contraindications, and technique of oral <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> challenge in patients suspected of having aspirin-exacerbated respiratory disease are discussed separately. (See  <a class="medical medical_review" href="/d/html/2085.html" rel="external">"Diagnostic challenge and desensitization protocols for NSAID reactions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Food additive challenge</strong> – Rarely, oral challenges with food additives (eg, sodium metabisulfite) are performed in specialized laboratories for the evaluation of suspected intolerance.(See <a class="local">'Food additive challenge'</a> above and  <a class="medical medical_review" href="/d/html/2405.html" rel="external">"Allergic and asthmatic reactions to food additives", section on 'Asthmatic symptoms'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cockcroft DW, Ruffin RE, Dolovich J, Hargreave FE. Allergen-induced increase in non-allergic bronchial reactivity. Clin Allergy 1977; 7:503.</a></li><li><a class="nounderline abstract_t">Coates AL, Wanger J, Cockcroft DW, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J 2017; 49.</a></li><li><a class="nounderline abstract_t">Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161:309.</a></li><li><a class="nounderline abstract_t">Laprise C, Laviolette M, Boutet M, Boulet LP. Asymptomatic airway hyperresponsiveness: relationships with airway inflammation and remodelling. Eur Respir J 1999; 14:63.</a></li><li><a class="nounderline abstract_t">Weiss ST, Van Natta ML, Zeiger RS. Relationship between increased airway responsiveness and asthma severity in the childhood asthma management program. Am J Respir Crit Care Med 2000; 162:50.</a></li><li><a class="nounderline abstract_t">Juniper EF, Frith PA, Hargreave FE. Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma. Thorax 1981; 36:575.</a></li><li><a class="nounderline abstract_t">Cockcroft DW, Killian DN, Mellon JJ, Hargreave FE. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977; 7:235.</a></li><li><a class="nounderline abstract_t">Lee P, Abisheganaden J, Chee CB, Wang YT. A new asthma severity index: a predictor of near-fatal asthma? Eur Respir J 2001; 18:272.</a></li><li><a class="nounderline abstract_t">Dixon AE, Pratley RE, Forgione PM, et al. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol 2011; 128:508.</a></li><li><a class="nounderline abstract_t">Hallstrand TS, Leuppi JD, Joos G, et al. ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing. Eur Respir J 2018; 52.</a></li><li class="breakAll">National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 10, 2012).</li><li><a class="nounderline abstract_t">Louis R, Satia I, Ojanguren I, et al. European Respiratory Society Guidelines for the Diagnosis of Asthma in Adults. Eur Respir J 2022.</a></li><li><a class="nounderline abstract_t">Goldstein MF, Pacana SM, Dvorin DJ, Dunsky EH. Retrospective analyses of methacholine inhalation challenges. Chest 1994; 105:1082.</a></li><li><a class="nounderline abstract_t">Rubinfeld AR, Pain MC. Perception of asthma. Lancet 1976; 1:882.</a></li><li><a class="nounderline abstract_t">Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis 1990; 141:640.</a></li><li><a class="nounderline abstract_t">Tepper RS, Wise RS, Covar R, et al. Asthma outcomes: pulmonary physiology. J Allergy Clin Immunol 2012; 129:S65.</a></li><li><a class="nounderline abstract_t">Dykewicz MS. Occupational asthma: current concepts in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2009; 123:519.</a></li><li><a class="nounderline abstract_t">Sterk PJ, Fabbri LM, Quanjer PH, et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16:53.</a></li><li><a class="nounderline abstract_t">Covar RA, Colvin R, Shapiro G, Strunk R. Safety of methacholine challenges in a multicenter pediatric asthma study. J Allergy Clin Immunol 2006; 117:709.</a></li><li><a class="nounderline abstract_t">Pratter MR, Bartter TC, Dubois J. Bronchodilator reversal of bronchospasm and symptoms incurred during methacholine bronchoprovocation challenge. Documentation of safety and time course. Chest 1993; 104:1342.</a></li><li><a class="nounderline abstract_t">Malerba M, Radaeli A, Politi A, et al. Cardiac arrhythmia monitoring during bronchial provocation test with methacholine. Chest 2003; 124:813.</a></li><li><a class="nounderline abstract_t">Martin RJ, Wanger JS, Irvin CG, et al. Methacholine challenge testing: safety of low starting FEV1. Asthma Clinical Research Network (ACRN). Chest 1997; 112:53.</a></li><li><a class="nounderline abstract_t">Cockcroft DW. Methacholine challenge methods. Chest 2008; 134:678.</a></li><li><a class="nounderline abstract_t">Chapman DG, Irvin CG, Kaminsky DA, et al. Influence of distinct asthma phenotypes on lung function following weight loss in the obese. Respirology 2014; 19:1170.</a></li><li><a class="nounderline abstract_t">Parker J, Tzeng A, Wayne S, et al. Validation of the clinical utility of sGaw as a response variable in methacholine challenge testing. Respirology 2023; 28:437.</a></li><li class="breakAll">National asthma education program. Expert Panel Report: Guidelines for the diagnosis and management of asthma. National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, Publication No. 91-3042, 1991.</li><li><a class="nounderline abstract_t">Blais CM, Davis BE, Cockcroft DW. Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium &amp; glycopyrronium against methacholine-induced bronchoconstriction in mild asthmatics. Respir Med 2016; 118:96.</a></li><li><a class="nounderline abstract_t">Sumino K, Sugar EA, Irvin CG, et al. Methacholine challenge test: diagnostic characteristics in asthmatic patients receiving controller medications. J Allergy Clin Immunol 2012; 130:69.</a></li><li><a class="nounderline abstract_t">Ryan G, Dolovich MB, Obminski G, et al. Standardization of inhalation provocation tests: influence of nebulizer output, particle size, and method of inhalation. J Allergy Clin Immunol 1981; 67:156.</a></li><li class="breakAll">Dolovich, MB. Technical factors influencing response to challenge aerosols. In: Airway Responsiveness: Measurement and Interpretation, Hargreave, FE, Woolcock, AJ (Eds), Astra Pharmaceuticals, Mississauga, Ontario 1985.</li><li><a class="nounderline abstract_t">Ryan G, Dolovich MB, Roberts RS, et al. Standardization of inhalation provocation tests: two techniques of aerosol generation and inhalation compared. Am Rev Respir Dis 1981; 123:195.</a></li><li><a class="nounderline abstract_t">Coates A, Culver B, Cockcroft D, et al. Characterizing Nebulizer Performance for Methacholine Challenge Tests. Am J Respir Crit Care Med 2018; 198:988.</a></li><li><a class="nounderline abstract_t">Cockcroft DW. Direct challenge tests: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010; 138:18S.</a></li><li><a class="nounderline abstract_t">Cockcroft DW, Davis BE. The bronchoprotective effect of inhaling methacholine by using total lung capacity inspirations has a marked influence on the interpretation of the test result. J Allergy Clin Immunol 2006; 117:1244.</a></li><li><a class="nounderline abstract_t">Hargreave FE, Ryan G, Thomson NC, et al. Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance. J Allergy Clin Immunol 1981; 68:347.</a></li><li><a class="nounderline abstract_t">Prieto L, Lopez V, Llusar R, et al. Differences in the response to methacholine between the tidal breathing and dosimeter methods: influence of the dose of bronchoconstrictor agent delivered to the mouth. Chest 2008; 134:699.</a></li><li><a class="nounderline abstract_t">Todd DC, Davis BE, Hurst TS, Cockcroft DW. Dosimeter methacholine challenge: comparison of maximal versus submaximal inhalations. J Allergy Clin Immunol 2004; 114:517.</a></li><li><a class="nounderline abstract_t">Anderson SD. Indirect challenge tests: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010; 138:25S.</a></li><li><a class="nounderline abstract_t">Toelle BG, Li J, Dalton M, Devadason SG. Subject discomfort associated with the histamine challenge in a population study. Respir Med 2002; 96:990.</a></li><li><a class="nounderline abstract_t">Chatham M, Bleecker ER, Smith PL, et al. A comparison of histamine, methacholine, and exercise airway reactivity in normal and asthmatic subjects. Am Rev Respir Dis 1982; 126:235.</a></li><li><a class="nounderline abstract_t">Fuller RW, Dixon CM, Cuss FM, Barnes PJ. Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis 1987; 135:176.</a></li><li><a class="nounderline abstract_t">Holgate ST, Mann JS, Cushley MJ. Adenosine as a bronchoconstrictor mediator in asthma and its antagonism by methylxanthines. J Allergy Clin Immunol 1984; 74:302.</a></li><li><a class="nounderline abstract_t">Anderson SD. Exercise-induced asthma and the use of hypertonic saline aerosol as a bronchial challenge. Respirology 1996; 1:175.</a></li><li><a class="nounderline abstract_t">van den Berge M, Kerstjens HA, Meijer RJ, et al. Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med 2001; 164:1127.</a></li><li><a class="nounderline abstract_t">Currie GP, Haggart K, Brannan JD, et al. Relationship between airway hyperresponsiveness to mannitol and adenosine monophosphate. Allergy 2003; 58:762.</a></li><li><a class="nounderline abstract_t">Prieto L, Bruno L, Gutiérrez V, et al. Airway responsiveness to adenosine 5'-monophosphate and exhaled nitric oxide measurements: predictive value as markers for reducing the dose of inhaled corticosteroids in asthmatic subjects. Chest 2003; 124:1325.</a></li><li><a class="nounderline abstract_t">Koskela HO, Hyvärinen L, Brannan JD, et al. Sensitivity and validity of three bronchial provocation tests to demonstrate the effect of inhaled corticosteroids in asthma. Chest 2003; 124:1341.</a></li><li><a class="nounderline abstract_t">Koskela HO, Hyvärinen L, Brannan JD, et al. Responsiveness to three bronchial provocation tests in patients with asthma. Chest 2003; 124:2171.</a></li><li><a class="nounderline abstract_t">Koskela HO, Hyvärinen L, Brannan JD, et al. Coughing during mannitol challenge is associated with asthma. Chest 2004; 125:1985.</a></li><li><a class="nounderline abstract_t">Brannan JD, Anderson SD, Perry CP, et al. The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline. Respir Res 2005; 6:144.</a></li><li><a class="nounderline abstract_t">Sverrild A, Porsbjerg C, Thomsen SF, Backer V. Diagnostic properties of inhaled mannitol in the diagnosis of asthma: a population study. J Allergy Clin Immunol 2009; 124:928.</a></li><li><a class="nounderline abstract_t">Anderson SD, Charlton B, Weiler JM, et al. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. Respir Res 2009; 10:4.</a></li><li><a class="nounderline abstract_t">O'Byrne PM, Gauvreau GM, Brannan JD. Provoked models of asthma: what have we learnt? Clin Exp Allergy 2009; 39:181.</a></li><li><a class="nounderline abstract_t">Porsbjerg C, Brannan JD, Anderson SD, Backer V. Relationship between airway responsiveness to mannitol and to methacholine and markers of airway inflammation, peak flow variability and quality of life in asthma patients. Clin Exp Allergy 2008; 38:43.</a></li><li><a class="nounderline abstract_t">Ramsdell JW. Adenosine airways responsiveness: what does it mean? Chest 2003; 123:971.</a></li><li><a class="nounderline abstract_t">Andregnette-Roscigno V, Fernández-Nieto M, Del Potro MG, et al. Methacholine is more sensitive than mannitol for evaluation of bronchial hyperresponsiveness in children with asthma. J Allergy Clin Immunol 2010; 126:869.</a></li><li><a class="nounderline abstract_t">Carlsen KH, Anderson SD, Bjermer L, et al. Exercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN. Allergy 2008; 63:387.</a></li><li class="breakAll">Beta2 adrenoreceptor agonists and the Olympic games in Beijing http://www.olympic.org/Documents/Reports/EN/en_report_1302.pdf (Accessed on September 23, 2011).</li><li class="breakAll">Aridol Test instructions. https://www.aridol.info/test-instructions/ (Accessed on October 13, 2020).</li><li><a class="nounderline abstract_t">Goldstein MF, Veza BA, Dunsky EH, et al. Comparisons of peak diurnal expiratory flow variation, postbronchodilator FEV(1) responses, and methacholine inhalation challenges in the evaluation of suspected asthma. Chest 2001; 119:1001.</a></li><li><a class="nounderline abstract_t">Cockcroft DW, Murdock KY, Berscheid BA, Gore BP. Sensitivity and specificity of histamine PC20 determination in a random selection of young college students. J Allergy Clin Immunol 1992; 89:23.</a></li><li><a class="nounderline abstract_t">Cockcroft DW, Berscheid BA, Murdock KY. Unimodal distribution of bronchial responsiveness to inhaled histamine in a random human population. Chest 1983; 83:751.</a></li><li><a class="nounderline abstract_t">Dodge RR, Burrows B. The prevalence and incidence of asthma and asthma-like symptoms in a general population sample. Am Rev Respir Dis 1980; 122:567.</a></li><li><a class="nounderline abstract_t">Paoletti P, Carrozzi L, Viegi G, et al. Distribution of bronchial responsiveness in a general population: effect of sex, age, smoking, and level of pulmonary function. Am J Respir Crit Care Med 1995; 151:1770.</a></li><li><a class="nounderline abstract_t">Hopp RJ, Townley RG, Biven RE, et al. The presence of airway reactivity before the development of asthma. Am Rev Respir Dis 1990; 141:2.</a></li><li><a class="nounderline abstract_t">Sumino K, Sugar EA, Irvin CG, et al. Variability of methacholine bronchoprovocation and the effect of inhaled corticosteroids in mild asthma. Ann Allergy Asthma Immunol 2014; 112:354.</a></li><li><a class="nounderline abstract_t">Anderson SD, Pearlman DS, Rundell KW, et al. Reproducibility of the airway response to an exercise protocol standardized for intensity, duration, and inspired air conditions, in subjects with symptoms suggestive of asthma. Respir Res 2010; 11:120.</a></li><li><a class="nounderline abstract_t">Christopher KL, Wood RP 2nd, Eckert RC, et al. Vocal-cord dysfunction presenting as asthma. N Engl J Med 1983; 308:1566.</a></li><li><a class="nounderline abstract_t">Eggleston PA, Rosenthal RR, Anderson SA, et al. Guidelines for the methodology of exercise challenge testing of asthmatics. Study Group on Exercise Challenge, Bronchoprovocation Committee, American Academy of Allergy. J Allergy Clin Immunol 1979; 64:642.</a></li><li><a class="nounderline abstract_t">Parsons JP, Hallstrand TS, Mastronarde JG, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med 2013; 187:1016.</a></li><li><a class="nounderline abstract_t">Rundell KW, Slee JB. Exercise and other indirect challenges to demonstrate asthma or exercise-induced bronchoconstriction in athletes. J Allergy Clin Immunol 2008; 122:238.</a></li><li><a class="nounderline abstract_t">Anderson SD. Issues in exercise-induced asthma. J Allergy Clin Immunol 1985; 76:763.</a></li><li><a class="nounderline abstract_t">Joos GF, O'Connor B, Anderson SD, et al. Indirect airway challenges. Eur Respir J 2003; 21:1050.</a></li><li><a class="nounderline abstract_t">American Thoracic Society, American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167:211.</a></li><li><a class="nounderline abstract_t">Fitch KD. An overview of asthma and airway hyper-responsiveness in Olympic athletes. Br J Sports Med 2012; 46:413.</a></li><li><a class="nounderline abstract_t">Molphy J, Dickinson J, Hu J, et al. Prevalence of bronchoconstriction induced by eucapnic voluntary hyperpnoea in recreationally active individuals. J Asthma 2014; 51:44.</a></li><li><a class="nounderline abstract_t">Chen WY, Horton DJ. Heat and water loss from the airways and exercise-induced asthma. Respiration 1977; 34:305.</a></li><li><a class="nounderline abstract_t">McFadden ER Jr. Exercise and asthma. N Engl J Med 1987; 317:502.</a></li><li><a class="nounderline abstract_t">Anderson SD, Sue-Chu M, Perry CP, et al. Bronchial challenges in athletes applying to inhale a beta2-agonist at the 2004 Summer Olympics. J Allergy Clin Immunol 2006; 117:767.</a></li><li><a class="nounderline abstract_t">Rundell KW, Anderson SD, Spiering BA, Judelson DA. Field exercise vs laboratory eucapnic voluntary hyperventilation to identify airway hyperresponsiveness in elite cold weather athletes. Chest 2004; 125:909.</a></li><li><a class="nounderline abstract_t">Evans TM, Rundell KW, Beck KC, et al. Airway narrowing measured by spirometry and impulse oscillometry following room temperature and cold temperature exercise. Chest 2005; 128:2412.</a></li><li><a class="nounderline abstract_t">Anderson SD, Kippelen P. Assessment and prevention of exercise-induced bronchoconstriction. Br J Sports Med 2012; 46:391.</a></li><li><a class="nounderline abstract_t">Brummel NE, Mastronarde JG, Rittinger D, et al. The clinical utility of eucapnic voluntary hyperventilation testing for the diagnosis of exercise-induced bronchospasm. J Asthma 2009; 46:683.</a></li><li><a class="nounderline abstract_t">Boulet LP, Gauvreau G, Boulay ME, et al. The allergen bronchoprovocation model: an important tool for the investigation of new asthma anti-inflammatory therapies. Allergy 2007; 62:1101.</a></li><li><a class="nounderline abstract_t">Vandenplas O, Malo JL. Inhalation challenges with agents causing occupational asthma. Eur Respir J 1997; 10:2612.</a></li><li><a class="nounderline abstract_t">Simon RA. Sulfite challenge for the diagnosis of sensitivity. Allergy Proc 1989; 10:357.</a></li><li class="breakAll">Spector SL, Farr RS. National Jewish Hospital experience with aspirin, tartrazine and analgesic oral challenge. In: Provocative challenge procedures: Bronchial, oral nasal and exercise, Spector SL (Ed), CRC Press, Boca Raton 1983. Vol 2.</li><li><a class="nounderline abstract_t">Vally H, Carr A, El-Saleh J, Thompson P. Wine-induced asthma: a placebo-controlled assessment of its pathogenesis. J Allergy Clin Immunol 1999; 103:41.</a></li><li><a class="nounderline abstract_t">Delohery J, Simmul R, Castle WD, Allen DH. The relationship of inhaled sulfur dioxide reactivity to ingested metabisulfite sensitivity in patients with asthma. Am Rev Respir Dis 1984; 130:1027.</a></li><li><a class="nounderline abstract_t">Bush RK, Zoratti E, Taylor SL. Diagnosis of sulfite and aspirin sensitivity. Clin Rev Allergy 1990; 8:159.</a></li><li class="breakAll">Farr, RS. Asthma induced by aspirin and metabisulfites. In: Current therapy of respiratory disease, Cherniack, RM (Eds), BC Decker, Philadelphia 1984.</li></ol></div><div id="topicVersionRevision">Topic 525 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/589783" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Allergen-induced increase in non-allergic bronchial reactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28461290" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10619836" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10489830" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Asymptomatic airway hyperresponsiveness: relationships with airway inflammation and remodelling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10903219" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Relationship between increased airway responsiveness and asthma severity in the childhood asthma management program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7031972" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/908121" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Bronchial reactivity to inhaled histamine: a method and clinical survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11529284" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A new asthma severity index: a predictor of near-fatal asthma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21782230" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30361249" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30361249" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35169025" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : European Respiratory Society Guidelines for the Diagnosis of Asthma in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8162729" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Retrospective analyses of methacholine inhalation challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/58147" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Perception of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2178528" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22386510" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Asthma outcomes: pulmonary physiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19281900" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Occupational asthma: current concepts in pathogenesis, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8499055" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16522478" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Safety of methacholine challenges in a multicenter pediatric asthma study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8222785" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Bronchodilator reversal of bronchospasm and symptoms incurred during methacholine bronchoprovocation challenge. Documentation of safety and time course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12970002" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cardiac arrhythmia monitoring during bronchial provocation test with methacholine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9228357" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Methacholine challenge testing: safety of low starting FEV1. Asthma Clinical Research Network (ACRN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18842907" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Methacholine challenge methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25138203" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Influence of distinct asthma phenotypes on lung function following weight loss in the obese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36478621" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Validation of the clinical utility of sGaw as a response variable in methacholine challenge testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36478621" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Validation of the clinical utility of sGaw as a response variable in methacholine challenge testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27578477" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium&amp;glycopyrronium against methacholine-induced bronchoconstriction in mild asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22465214" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Methacholine challenge test: diagnostic characteristics in asthmatic patients receiving controller medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7451782" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Standardization of inhalation provocation tests: influence of nebulizer output, particle size, and method of inhalation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7451782" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Standardization of inhalation provocation tests: influence of nebulizer output, particle size, and method of inhalation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7235358" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Standardization of inhalation provocation tests: two techniques of aerosol generation and inhalation compared.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30160985" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Characterizing Nebulizer Performance for Methacholine Challenge Tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20668014" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Direct challenge tests: Airway hyperresponsiveness in asthma: its measurement and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16750982" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The bronchoprotective effect of inhaling methacholine by using total lung capacity inspirations has a marked influence on the interpretation of the test result.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7028842" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18625670" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Differences in the response to methacholine between the tidal breathing and dosimeter methods: influence of the dose of bronchoconstrictor agent delivered to the mouth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15356550" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Dosimeter methacholine challenge: comparison of maximal versus submaximal inhalations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20668015" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Indirect challenge tests: Airway hyperresponsiveness in asthma: its measurement and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12477213" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Subject discomfort associated with the histamine challenge in a population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7103250" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A comparison of histamine, methacholine, and exercise airway reactivity in normal and asthmatic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3541715" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bradykinin-induced bronchoconstriction in humans. Mode of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6470364" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adenosine as a bronchoconstrictor mediator in asthma and its antagonism by methylxanthines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9424393" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Exercise-induced asthma and the use of hypertonic saline aerosol as a bronchial challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11673197" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12859555" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Relationship between airway hyperresponsiveness to mannitol and adenosine monophosphate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14555562" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Airway responsiveness to adenosine 5'-monophosphate and exhaled nitric oxide measurements: predictive value as markers for reducing the dose of inhaled corticosteroids in asthmatic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14555564" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Sensitivity and validity of three bronchial provocation tests to demonstrate the effect of inhaled corticosteroids in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14665497" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Responsiveness to three bronchial provocation tests in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15189912" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Coughing during mannitol challenge is associated with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16336673" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19665779" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Diagnostic properties of inhaled mannitol in the diagnosis of asthma: a population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19161635" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19187330" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Provoked models of asthma: what have we learnt?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18028458" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Relationship between airway responsiveness to mannitol and to methacholine and markers of airway inflammation, peak flow variability and quality of life in asthma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12684275" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Adenosine airways responsiveness: what does it mean?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20920775" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Methacholine is more sensitive than mannitol for evaluation of bronchial hyperresponsiveness in children with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18315727" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Exercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18315727" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Exercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18315727" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Exercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11296161" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Comparisons of peak diurnal expiratory flow variation, postbronchodilator FEV(1) responses, and methacholine inhalation challenges in the evaluation of suspected asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1730837" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sensitivity and specificity of histamine PC20 determination in a random selection of young college students.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6839815" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Unimodal distribution of bronchial responsiveness to inhaled histamine in a random human population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7436122" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The prevalence and incidence of asthma and asthma-like symptoms in a general population sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7767519" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Distribution of bronchial responsiveness in a general population: effect of sex, age, smoking, and level of pulmonary function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2404438" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The presence of airway reactivity before the development of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24507830" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Variability of methacholine bronchoprovocation and the effect of inhaled corticosteroids in mild asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20807446" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Reproducibility of the airway response to an exercise protocol standardized for intensity, duration, and inspired air conditions, in subjects with symptoms suggestive of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6406891" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Vocal-cord dysfunction presenting as asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/512260" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Guidelines for the methodology of exercise challenge testing of asthmatics. Study Group on Exercise Challenge, Bronchoprovocation Committee, American Academy of Allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23634861" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18678339" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Exercise and other indirect challenges to demonstrate asthma or exercise-induced bronchoconstriction in athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2999208" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Issues in exercise-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12797503" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Indirect airway challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12524257" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : ATS/ACCP Statement on cardiopulmonary exercise testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22228581" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : An overview of asthma and airway hyper-responsiveness in Olympic athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23987567" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Prevalence of bronchoconstriction induced by eucapnic voluntary hyperpnoea in recreationally active individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/918355" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Heat and water loss from the airways and exercise-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3614295" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Exercise and asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16630932" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Bronchial challenges in athletes applying to inhale a beta2-agonist at the 2004 Summer Olympics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15006949" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Field exercise vs laboratory eucapnic voluntary hyperventilation to identify airway hyperresponsiveness in elite cold weather athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236903" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Airway narrowing measured by spirometry and impulse oscillometry following room temperature and cold temperature exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22247297" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Assessment and prevention of exercise-induced bronchoconstriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19728205" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The clinical utility of eucapnic voluntary hyperventilation testing for the diagnosis of exercise-induced bronchospasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17845579" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The allergen bronchoprovocation model: an important tool for the investigation of new asthma anti-inflammatory therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9426105" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Inhalation challenges with agents causing occupational asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2684757" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Sulfite challenge for the diagnosis of sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2684757" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Sulfite challenge for the diagnosis of sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9893183" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Wine-induced asthma: a placebo-controlled assessment of its pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6507999" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The relationship of inhaled sulfur dioxide reactivity to ingested metabisulfite sensitivity in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2292093" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Diagnosis of sulfite and aspirin sensitivity.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
